Education
About Us
Working with TipRanks
Follow Us
Better Therapeutics, Inc. (BTTX)
OTHER OTC:BTTX
Total Valuation
Better Therapeutics has a market cap or net worth of $5.43K. The enterprise value is ―.
Market Cap$5.43K
Enterprise Value―
Share Statistics
Better Therapeutics has 54,352,497 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,352,497
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Better Therapeutics’s return on equity (ROE) is 44.23 and return on invested capital (ROIC) is -273.72%.
Return on Equity (ROE)44.23
Return on Assets (ROA)-1.73
Return on Invested Capital (ROIC)-273.72%
Return on Capital Employed (ROCE)-4.05
Revenue Per Employee0.00
Profits Per Employee-736.30K
Employee Count54
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Better Therapeutics is ―. Better Therapeutics’s PEG ratio is 0.56.
PE Ratio―
PS Ratio0.00
PB Ratio-29.09
Price to Fair Value-29.09
Price to FCF-0.87
Price to Operating Cash Flow>-0.01
PEG Ratio0.56
Income Statement
In the last 12 months, Better Therapeutics had revenue of 0.00 and earned -39.76M in profits. Earnings per share was -1.69.
Revenue0.00
Gross Profit-2.73M
Operating Income-38.26M
Pretax Income-39.75M
Net Income-39.76M
EBITDA-38.21M
Earnings Per Share (EPS)-1.69
Cash Flow
In the last 12 months, operating cash flow was -26.08M and capital expenditures -1.39M, giving a free cash flow of -27.47M billion.
Operating Cash Flow-26.08M
Free Cash Flow-27.47M
Free Cash Flow per Share-0.51
Dividends & Yields
Better Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta199.24
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)0.00
Important Dates
Better Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Better Therapeutics as a current ratio of 1.37, with Debt / Equity ratio of -1655.17%
Current Ratio1.37
Quick Ratio1.37
Debt to Market Cap0.57
Net Debt to EBITDA0.02
Interest Coverage Ratio-25.66
Taxes
In the past 12 months, Better Therapeutics has paid 7.00K in taxes.
Income Tax7.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Better Therapeutics EV to EBITDA ratio is -0.66, with an EV/FCF ratio of -0.84.
EV to Sales0.00
EV to EBITDA-0.66
EV to Free Cash Flow-0.84
EV to Operating Cash Flow-0.87
Balance Sheet
Better Therapeutics has $6.60M in cash and marketable securities with $14.31M in debt, giving a net cash position of -$7.71M billion.
Cash & Marketable Securities$6.60M
Total Debt$14.31M
Net Cash-$7.71M
Net Cash Per Share-$0.14
Tangible Book Value Per Share-$0.20
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Better Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―